Investors

Excellent revenue growth of 21.2% at the end of September at comparable exchange rates and scope (+16.4% at constant rates and real scope), driven by a very solid third-quarter performance again in all areas

Virbac and Jectas Innovators are proud to announce the signature of a collaborative agreement for the development of animal health vaccine(s).

Significant increase in operating profit from ordinary activities for the first half of 2021 due to the sound market performance and dynamism of our business